# Charles River Laboratories Degrader Discovery Toolbox: Facilitating the Rapid and Efficient Development of PROTACs®





William Esmieu<sup>a</sup>, Katherine Jones<sup>a</sup>, Daniel Webb<sup>a,b</sup>, Ryan Tinson<sup>a</sup>, James Lewis<sup>a</sup>, Isabelle Lemasson<sup>a</sup>, Giovanni Pinna<sup>a</sup>, Alka Chauhan<sup>a</sup>, Mark Chambers<sup>a</sup>, Nathalie Tiberghien<sup>a</sup>, Mike Lipkin<sup>a</sup>, Andrew Roupany<sup>a</sup>, Liz Saville-Stones<sup>a</sup>, Laura Copeland<sup>a</sup>, Serena Yeung<sup>a</sup>, Charlotte Smith<sup>a</sup>, Natsuko Macabuag<sup>a</sup>, Ruzica Bago<sup>a</sup>, Steve Clifton<sup>a</sup>, William J. Kerr<sup>b</sup>, David M. Lindsay<sup>b</sup>, Laura C. Paterson<sup>b</sup>.

#### <sup>a</sup> Charles River Early Discovery, UK; <sup>b</sup> University of Strathclyde, UK.


## Introduction

Proteolysis targeting chimeras (PROTACs<sup>®</sup>) are heterobifunctional molecules that exploit the body's endogenous ubiquitin proteasome system (UPS) to induce targeted protein degradation. PROTACs® consist of two ligands, which bind to the target protein of interest (POI) and an E3 ubiquitin ligase, connected by a linker. The formation of a productive POI-PROTAC<sup>®</sup>-E3 ligase ternary complex (TC) facilitates the (poly)ubiquitination of the target protein, marking it for degradation by the 26S proteasome.

The length and composition of the linker has a significant impact on the physicochemical properties and bioactivity of the PROTAC<sup>®</sup>. Nevertheless, linker optimisation can be a time-consuming, iterative process that must be carried out for each ligand pair.<sup>1</sup> A recent statistical analysis of 422 reported degraders highlighted that 64% of PROTACs<sup>®</sup> employed simple (poly)ethylene glycol (PEG) or alkyl linkers.<sup>2</sup>

We set out to design a degrader toolbox, comprising of linkers attached to E3 ligase ligands, that would enable us to shorten the time required to achieve the following goals in partnership with our collaborators:

- Establish target degradability.
- Investigate how linker affects ternary complex formation.



4.95

5.83

6.71

• Provide a set of degraders covering a range of physicochemical property space.

## Linkerology

Optimisation of physicochemical parameters is essential to develop successful degraders, and the linker has a significant impact on these properties.

- Formation of intramolecular hydrogen bonds near cell membranes has been identified as • an important factor in degrader permeability. This 'Chameleonicity' is influenced directly by the length, flexibility, and heteroatomic composition of the linker.<sup>3</sup>
- Compound acidity/basicity has a significant impact on physicochemical properties. Simple  $\bullet$ changes within the linker, for example changing an amide attachment vector to an amine, or switching a piperazine for a piperidine ring, can have a significant impact on PROTAC solubility and permeability.


#### Methodology 3

To achieve our objectives, a degrader toolbox of late-stage, functionalised building blocks was assembled.


- A selection of E3 ligase binders were conjugated to a diverse range of linkers.
- A variety of linker attachment points were employed, requiring minimal alteration to attach a POI ligand.
- Linker design was inspired by reported orally bioavailable degraders to improve the likelihood of achieving good permeability and solubility.


### **ALK2 Degrader Case Study**

- Activin Receptor-like Kinase 2 (ALK2) is a protein implicated in conditions including Fibrodysplasia Ossificans Progresiva (FOP) disorder and Diffuse Intrinsic Pontine Glioma (DIPG).
- M4K2009 is a potent and selective ALK2 inhibitor developed as a potential therapy for DIPG.<sup>4,5</sup>
- **ALK2** degradation was explored as a complementary approach to inhibition.



- The CRL Degrader Discovery Toolbox was developed to contain a variety of highly functionalised intermediates (E3 ligands + Linkers), enabling the rapid and efficient synthesis of degraders from a POI ligand.
- We used intermediates from the toolbox to synthesise a set of 15 ALK2 degraders, which were used to establish target degradability.
- The degraders were analysed in silico, to demonstrate the range of chemical space accessible from a single ligand, using our toolbox.





Target Engaged  $\rightarrow$  Target Degraded  $\rightarrow$  ADME Investigated  $\rightarrow$  Further Optimisation Planned



• The CRL Degrader Discovery Toolbox is a powerful instrument for the rapid and efficient synthesis of degrader sets to establish target degradability.

E3 Ligands



PSA

180

170

1. Troup, R. I.; Fallan, C.; Baud, M. G. J.; Exploration of Targeted Anti-tumor Therapy 2020, 1 (5), 273-312.

• A continually evolving linker library covering a variety of chemical space has been established.

• This approach operates in synergy with our other drug discovery offerings to enable efficient investigation of protein degradation as an alternative modality to small molecule inhibition.

2. Maple, H. J.; Clayden, N.; Baron, A.; Stacey, C.; Medchemcomm 2019, 10 (10), 1755-1764. 3. Whitty, A.; Zhong, M.; Viarengo, L.; Beglov, D.; Hall, D. R.; Vajda, S.; Drug Discov Today 2016, 21 (5), 712-717. 4. https://m4kpharma.com/blog/. 5. Smil, D.; Wong, J. F.; Williams, E. P.; Adamson, R. J.; Howarth, A.; McLeod, D. A.; Mamai, A.; Kim, S.; Wilson, B. J.; Kiyota, T.; et al.; *Journal of Medicinal Chemistry* **2020**, *63* (17), 10061-10085.

PROTAC<sup>®</sup> is a registered trademark of Arvinas Operations Inc.